Dr Reddy's Laboratories Common Stock Net 2010-2024 | RDY

Dr Reddy's Laboratories common stock net from 2010 to 2024. Common stock net can be defined as the value of common equity ownership.
  • Dr Reddy's Laboratories common stock net for the quarter ending September 30, 2024 was $0.010B, a 0% increase year-over-year.
  • Dr Reddy's Laboratories common stock net for 2024 was $0.01B, a 0% decline from 2023.
  • Dr Reddy's Laboratories common stock net for 2023 was $0.01B, a 9.09% decline from 2022.
  • Dr Reddy's Laboratories common stock net for 2022 was $0.011B, a 0% decline from 2021.
Dr Reddy's Laboratories Annual Common Stock Net
(Millions of US $)
2024 $10
2023 $10
2022 $11
2021 $11
2020 $11
2019 $12
2018 $13
2017 $13
2016 $13
2015 $14
2014 $14
2013 $16
2012 $17
2011 $19
2010 $19
2009 $17
Dr Reddy's Laboratories Quarterly Common Stock Net
(Millions of US $)
2024-09-30 $10
2024-06-30 $10
2024-03-31 $10
2023-12-31 $10
2023-09-30 $10
2023-06-30 $10
2023-03-31 $10
2022-12-31 $10
2022-09-30 $10
2022-06-30 $11
2022-03-31 $11
2021-12-31 $11
2021-09-30 $11
2021-06-30 $11
2021-03-31 $11
2020-12-31 $11
2020-09-30 $11
2020-06-30 $11
2020-03-31 $11
2019-12-31 $12
2019-09-30 $12
2019-06-30 $12
2019-03-31 $12
2018-12-31 $12
2018-09-30 $11
2018-06-30 $12
2018-03-31 $13
2017-12-31 $13
2017-09-30 $13
2017-06-30 $13
2017-03-31 $13
2016-12-31 $12
2016-09-30 $12
2016-06-30 $12
2016-03-31 $13
2015-12-31 $13
2015-09-30 $13
2015-06-30 $13
2015-03-31 $14
2014-12-31 $14
2014-09-30 $14
2014-06-30 $14
2014-03-31 $14
2013-12-31 $14
2013-09-30 $14
2013-06-30 $14
2013-03-31 $16
2012-12-31 $16
2012-09-30 $16
2012-06-30 $15
2012-03-31 $17
2011-12-31 $16
2011-09-30 $17
2011-06-30 $19
2011-03-31 $19
2010-12-31 $19
2010-09-30 $18
2010-06-30 $18
2010-03-31 $19
2009-12-31 $18
2009-09-30 $17
2009-06-30 $18
2009-03-31 $17
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $11.677B $3.350B
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.350B 6.35
BridgeBio Pharma (BBIO) United States $4.392B 0.00
Bausch Health Cos (BHC) Canada $3.009B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.142B 12.88
Supernus Pharmaceuticals (SUPN) United States $1.978B 26.93
Taysha Gene Therapies (TSHA) United States $0.447B 31.14
Personalis (PSNL) United States $0.239B 0.00
Assembly Biosciences (ASMB) United States $0.094B 0.00
Sol-Gel Technologies (SLGL) Israel $0.013B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00